Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Effect of Tofacitinib on Live Vaccine Responses

Richard Quinn  |  February 26, 2016

New research indicates that vaccination for the herpes zoster virus in patients with rheumatoid arthritis starting tofacitinib appears to be both safe and useful. Rheumatologists may want to check the patient’s pre-existing immunity status prior to administering the vaccine…

Cholesterol Levels in Patients with RA Starting Methotrexate

Arthritis & Rheumatology  |  February 25, 2016

Although research regarding the increased cardiovascular (CV) morbidity and mortality in rheumatoid arthritis (RA) has burgeoned in recent years, the need remains for a better understanding of the effects of widely used DMARDs on CV risk and risk factors in RA patients. These authors set out to evaluate the long-term changes in cholesterol levels in patients with early RA. Decreases in RA disease activity over long-term follow-up were associated with increases in cholesterol levels in patients with early RA treated with either biologic or nonbiologic therapies…

Verily, Vanderbilt to Test Enrollment in U.S. Precision Medicine Pilot

Reuters Staff  |  February 25, 2016

(Reuters)—The National Institutes of Health on Thursday named Verily, formerly Google Life Sciences, as advisor to Nashville’s Vanderbilt University in a pilot program to launch the Precision Medicine Initiative outlined by President Barack Obama last year. The program aims to enroll 79,000 volunteer participants by the end of this year to supply personal data that…

U.S. Senate Moves Closer to Confirming Califf to Lead FDA

Toni Clarke  |  February 24, 2016

WASHINGTON (Reuters)—The U.S. Senate on Monday moved closer to confirming Dr. Robert Califf to lead the U.S. Food and Drug Administration, overriding opposition from several senators who had sought to block a vote on the issue. In a procedural move designed to prevent the opponents from blocking the confirmation indefinitely, the Senate voted 80 to…

Hidradenitis Suppurativa Tied to Higher Mortality

David Douglas  |  February 24, 2016

NEW YORK (Reuters Health)—Hidradenitis suppurativa (HS) is associated with a significantly increased risk of adverse cardiovascular (CV) outcomes and all-cause mortality, according to Danish researchers. HS is a chronic, inflammatory skin disease and is most common in women. It is typically diagnosed after long delays, Dr. Alexander Egeberg of the University of Copenhagen and colleagues…

Apremilast Proves Effective for PsA with Skin Involvement

Michele B. Kaufman, PharmD, BCGP  |  February 24, 2016

A recent Phase 3 clinical trial found apremilast safe and effective for treating patients with active psoriatic arthritis and skin symptoms who found conventional and biologic DMARDs ineffective…

U.S. & EU Regulators Urge Indian Drug Companies to Step Up Standards

Zeba Siddiqui  |  February 23, 2016

MUMBAI (Reuters)—U.S. and EU drug regulators called upon India’s pharmaceutical sector on Tuesday to step up efforts to improve manufacturing standards and ensure the reliability of data if it is to maintain its dominance in the generic drugs industry. India’s $15 billion pharmaceutical industry, an increasingly important global supplier of cheaper generic medicines, has been…

Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial

Reuters Staff  |  February 23, 2016

(Reuters)—Amgen Inc. and Belgium-based UCB SA said on Monday that their osteoporosis drug met all the primary endpoints by reducing the incidence of new vertebral fracture in postmenopausal women with osteoporosis in a late-stage study. The topline results, from a Fracture study in postmenopausal women with osteoporosis (FRAME), showed that the drug romosozumab met a…

Dermatology & Immunology: Skin Issues Can Present Challenges

Thomas R. Collins  |  February 23, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

U.S. Proposes Hike in Medicare Advantage Payments; Insurer Shares Rise

Caroline Humer  |  February 22, 2016

NEW YORK (Reuters)—The U.S. government on Friday proposed raising payments by 1.35% on average next year to the health insurers who offer Medicare Advantage health benefits to elderly and disabled Americans. Payments to insurers will vary under the 2017 Medicare Advantage proposal, based on the region the plans are sold and on the size of…

  • « Previous Page
  • 1
  • …
  • 520
  • 521
  • 522
  • 523
  • 524
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences